Cibinetide (ARA290) is an EPO-derivative, acting as a specific agonist of erythropoietin/CD131 heteroreceptor, and used for neurological disease treatment.
性状
Solid
体外研究(In Vitro)
Cibinetide (ARA290) enhances the proliferation, migration, and resistance to H2O2-induced apoptosis of endothelial colony-forming cells (ECFCs). Cibinetide (ARA290) is an EPO-analog peptide without hematopoietic side-effects but may have neurotrophic and antidepressant effects. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
After ECFC transplantation to mice with CLI, a single Cibinetide (ARA290) injection enhances the ischemic/non-ischemic ratio of hindlimb blood flow and capillary density after 28 days and the homing of radiolabeled transplanted cells to the ischemic leg 4?h after transplantation. Cibinetide (ARA290; 30 μg/kg, s.c.) prevents progressive worsening of glucose control without affecting body weight of rats. Cibinetide significantly decreases glucose AUCs in IPGTT in GK rats. Low-dosage Cibinetide (35 μg/kg, i.p.) treatment only slightly attenuates the EAE severity in rats. Cibinetide-treating group (70 μg/kg, i.p.) significantly delays the onset, decreases the neurologic severity and shortens the duration of EAE in a dose-dependent way. has not independently confirmed the accuracy of these methods. They are for reference onl
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Sealed storage, away from moisturePowder -80°C 2 years;-20°C 1 year
ClinicalTrial
SequenceShortening
{Glp}-EQLERALNSS
Sequence
{Glp}-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser
参考文献
[1]. Hache G, et al. ARA290, a Specific Agonist of Erythropoietin/CD131 Heteroreceptor, Improves Circulating Endothelial Progenitors Angiogenic Potential and Homing Ability. Shock. 2016 Oct;46(4):390-7[2]. Carole Muller, et al. ARA290 Improves Insulin Release and Glucose Tolerance in Type 2 Diabetic Goto-Kakizaki Rats. Mol Med. 2015; 21(1): 969–978